

Lumax Industries

Sensex: 32238

CMP: INR 1350

Target : INR 1346



Auto ancillary

Lumax Industries Ltd. (Lumax) reported revenues of INR 3483 mn (up 15% YoY & down 9.7% QoQ), EBIDTA of INR 245 mn (up 5.1% YoY & down 3.5% QoQ) with EBIDTA margin (Excl. Other Income) at 7% (7.7% YoY). Consolidated PAT was reported at INR 152 mn (up by 17.8% YoY and up 113.4% QoQ). RM cost as % of sales jumped to 66.4% in 1Q FY18 (63.7% YoY) as ~ INR 65 mn increase in RM cost has been passed by vendors but the company is still negotiating with clients for price hikes. With positive outlook for the Passenger vehicle (CAGR of 10-12% between FY17-19E) & Two wheeler industry (CAGR of 5-7% between FY17-19E) and esteemed clientele consisting of Maruti (35% of revenue), M&M (11%), HMSI (9%), Honda Cars (9%) and Hero Motocorp (9%) among others, we expect Lumax Industries to clock revenue and PAT CAGR of 9.2% and 18% respectively between FY17-19E. We incorporate FY19 numbers and recommend HOLD rating with a target price of INR 1346 based on 20x FY19E earnings.

Revenue up 15%

Lumax's Q1FY18 revenue was up 15% YoY (down 9.7% QoQ) to INR 3483 mn as the company reported volume growth of ~3% YoY while remaining part of growth was attributed to higher value added products. The sales mix for the quarter for the lamps business stood as follows - Maruti- 31%, M&M- 11%, Hero Motocorp- 10%, HMSI- 12% and Honda Cars- 8%. Contribution from HMSI has gone up from 9% in FY17 to 12% in Q1 FY18. With exposure to fastest growing OEMS across the industries, we expect revenue of Lumax to grow at a faster pace than broader automotive industry.

Margins down 66.5 bps YoY

Lumax reported EBITDA (Excl Other Income) growth of 5.1% YoY to INR 245 mn and margins contracted by 66.5 bps YoY to 7% in Q1FY18. Raw material costs as a % of sales increased 268 bps YoY to 66.4% due to overall increase in commodity costs. The company has witnessed price increase from the vendors but are not able to pass on the same to the clients. Management estimated additional RM cost of INR 65 mn on the back of inability to pass on price increases. With negotiations being in advanced stages, we expect Lumax to pass on the incremental RM cost in next couple of quarters. Employee costs as % of sales fell 13 bps to 12.4% whereas other expenses as % of sales witnessed sharp decline of 188 bps to 14.1%.

CAPEX plans

The company has no significant CAPEX plans and it intends to invest INR 450-500 mn in each of FY18 & FY19 for product


development and maintenance CAPEX. On the product development side, the company is working on LED light projects with OEMs like Maruti, Honda, Tata Motors, etc. Currently Lumax garners less than 5% of revenue from LED business and expects the same to grow to 15%-20% over the next 3-5 years. With increasing contribution of higher margin LED products, we expect EBITDAM to expand by ~89 bps by FY19. The current capacity utilization stands at ~85-90% and Lumax can increase the number of working shifts to increase capacity. Gujarat Facility is expected to be operational in November 2017. This facility will be catering to MSIL, Tata Motors and HMSI.

Outlook & Valuation

~40% market share in domestic passenger car industry coupled with superior technological knowhow places the company on a strong footing. Lumax, being a preferred choice of OEMs, is set to benefit from significant increase in production of cars (given the current low level of penetration of ~20 cars/1000 persons in India v/s ~126 in Brazil & 806 in USA and emergence of India as an export hub). In the near term, growth in PV Ind (FY17-19E CAGR- 10-12%) & 2-Wheeler Ind (FY17-19E CAGR- 5-7%) ensures decent revenue visibility. We expect Lumax Industries to clock revenue and PAT CAGR of 9.2% and 18% respectively between FY17-19E. We incorporate FY19 numbers and recommend HOLD rating with a target price of INR 1346 based on 20x FY19E earnings.

Shareholding (%)	Jun-17
Promoters	73.53
FIIIs	2.21
DIIIs	1.66
Others	22.6

Relative Price Performance






Key Data	
BSE Code	517206
NSE Code	LUMAXIND
Bloomberg Code	LUMX IN
Reuters Code	LUMA.BO
Shares Outstanding (mn)	9.35
Face Value	10
Mcap (INR bn)	12.97
52 Week H/L	1609.90/649.00
2W Avg. Qty.NSE	9027
Free Float (INR Bn)	3.43
Beta	1.59

(INR mn)	FY16	FY17	FY18E	FY19E
Net Sales	12552	12998	14224	15497
Growth (%)	9.9%	3.6%	9.4%	9.0%
EBIDTAM (%)	7.1%	7.7%	8.2%	8.6%
Adj. PAT	374	452	519	629
Growth (%)	125.5%	20.9%	14.8%	21.3%
Adj. EPS (INR)	40.0	48.3	55.5	67.3
P/E (x)	10.5	28.4	24.7	20.4
EV/EBIDTA	4.4	12.2	10.8	9.0
EV/Sales	0.3	1.0	0.9	0.8
RoACE (%)	7.1%	8.0%	8.6%	9.5%
RoAE (%)	19.4	20.3	20.0	21.0

Quarterly Financials

Particulars (INR Mn)	Jun-17	Jun-16	Mar-17	% Chg (YoY)	% Chg (QoQ)
Revenue (Net of Excise Duty)	3,483	3,028	3,859	15.0	-9.7
RM Cost	2,312	1,929	2,672	19.9	-13.5
Operating & Manufacturing Expenses	493	485	517	1.5	-4.7
Employee Cost	434	381	416	13.8	4.2
Miscellaneous Expenses				NA	NA
Total Expenditure	3,238	2,795	3,605	15.9	-10.2
EBITDA	245	233	254	5.1	-3.5
Depreciation	112	102	99	9.6	13.3
Other Income	19	13	20	44.6	-5.1
EBIT	152	144	175	5.5	-13.1
Interest	13	30	23	-58.1	-45.2
Exceptional Items	-	-	-	NA	NA
PBT	140	114	152	22.4	-8.2
Tax	59	22	45	167.2	29.2
Profit After Tax	81	92	107	-12.1	-24.2
Share of Associate	71	37	-36	93.2	-297.5
Consolidated PAT	152	129	71	17.8	113.4
Equity	93.5	93.5	93.5		
Face Value	10.0	10.0	10.0		
EPS	16.2	13.8	7.6	17.8	113.3
% of Sales				bps	bps
Raw Material Cost	66.4	63.7	69.2	267.9	-286.9
Employee Expenses	12.4	12.6	10.8	-13.1	166.7
Other Expenses	14.1	16.0	13.4	-188.3	74.6
OPM Excl Other income	7.0	7.7	6.6	-66.5	45.5
EBITDAM	7.6	8.1	7.1	-55.4	48.2
PATM	2.3	3.0	2.8	-71.7	-44.2



Financials

Income Statement

Y/E Mar (INR mn)	FY16	FY17	FY18E	FY19E
Net Sales	12552	12998	14224	15497
% Growth	9.9%	3.6%	9.4%	9.0%
RM Cost	8132	8020	8776	9562
% Growth	2.6%	-1.4%	9.4%	8.9%
Employee Expenses	1413	1583	1678	1779
% Growth	13.3%	12.1%	6.0%	6.0%
Oth Expense	2121	2396	2607	2827
Total Op Exp	11666	12000	13062	14168
EBIDTA (excl OI)	886	998	1161	1328
% Growth	49.3%	12.7%	16.4%	14.4%
EBITDA Margin %	7.1%	7.7%	8.2%	8.6%
Dep./Amortization	379	404	431	466
Other Income	44	62	29	64
EBIT	550	656	759	927
EBIT Margin %	4.4%	5.0%	5.3%	6.0%
Interest Expense	134	114	110	120
Exceptional Items	0	0	0	0
EBT	416	542	649	807
Tax Expenses	42	90	130	177
PAT	374	452	519	629
% Growth	125.5%	20.9%	14.8%	21.3%
APAT Margin %	3.0%	3.5%	3.6%	4.1%

Key Ratios

Y/E Mar	FY16	FY17	FY18E	FY19E
Per Share Data (INR)				
Reported EPS	40.0	48.3	55.5	67.3
Adj. EPS	40.0	48.3	55.5	67.3
Growth (%)				
CEPS	80.5	91.6	101.6	117.1
DPS	12.0	14.5	16.7	20.2
BVPS	218.4	258.5	297.4	344.5
Return Ratios (%)				
RoACE	7.1%	8.0%	8.6%	9.5%
RoANW	19.4%	20.3%	20.0%	21.0%
RoIC	6.5%	6.9%	7.1%	7.7%
Liquidity Ratios				
Net Debt/Equity	0.5	0.3	0.2	(0.0)
Interest Coverage Ratio	4.1	5.7	6.9	7.7
Current Ratio	0.6	0.6	0.7	0.8
Quick Ratio	0.3	0.4	0.4	0.5
Efficiency Ratios				
Asset Turnover Ratio	1.61	1.59	1.61	1.59
Inventory Days	32.7	35.3	33.7	33.9
Debtor Days	52.7	53.6	52.3	52.3
Creditor Days	96.9	104.7	100.0	100.4
Valuation Ratios				
P/E (x)	10.5	28.4	24.7	20.4
P/BV (x)	1.9	5.3	4.6	4.0
P/CEPS (x)	5.2	15.0	13.5	11.7
Dividend Yield (%)	0.0	0.0	0.0	0.0
EV/Net Sales (x)	0.3	1.0	0.9	0.8
EV/EBIDTA (x)	4.4	12.2	10.8	9.0

Balance Sheet

Y/E Mar (INR mn)	FY16	FY17	FY18E	FY19E
Share Capital	93	93	93	93
Reserves and Surplus	1948	2323	2686	3127
Total Networkth	2042	2417	2780	3220
Long Term Debt	106	36	0	0
Short Term Debt	848	790	896	977
Total Debt	954	827	896	977
Net Deferred Tax Liability	194	279	285	291
Other Liabilities	316	332	358	382
Sources of Funds	3507	3855	4320	4870
Net Block	4080	3874	3943	4007
CWIP	170	525	775	652
Investments	45	45	45	45
Current Assets	3322	3472	4026	5036
Current Liabilities	4437	4558	4922	5362
Net Current Assets	-1115	-1086	-895	-326
Other Assets	326	496	452	491
Application of Funds	3507	3855	4320	4870

Cash Flow

Y/E Mar (INR mn)	FY16	FY17	FY18E	FY19E
PBT	416	542	649	807
Add: Depreciation	379	404	431	466
Add: Interest paid	134	114	110	120
Change in Working Capital	(28)	(108)	237	190
Less: Taxes	(42)	(90)	(130)	(177)
Cash Flow from operations (a)	859	862	1,298	1,405
Change in Fixed Assets	(500)	(198)	(500)	(530)
Change in CWIP	92	(354)	(250)	122
Change in Investments	-	-	-	-
Others	(81)	(170)	44	(39)
Cash Flow from Investing (b)	(490)	(723)	(706)	(447)
Change in Equity	-	-	-	-
Debt Raised/(Repaid)	(270)	(69)	(36)	-
Dividend paid	(112)	(136)	(156)	(189)
Interest paid	(134)	(114)	(110)	(120)
Others	(7)	159	32	30
Cash Flow from Financing (c)	(524)	(160)	(271)	(279)
Net Change in Cash (a+b+c)	(156)	(21)	322	679
Opening Cash	190	35	14	335
Closing Cash	35	14	335	1,015

Sharad Avasthi

Head - Equity Research

sharad.avasthi@spagroupindia.com

Tel.: +91-022-4289 5600

Ext.205

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act, 1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited. The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets. A graph of daily closing prices of securities is available at www.nseindia.com and http://economicstimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of SPA Securities.

List of Associates as per SEBI (Research Analyst) Regulations, 2014

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month	No
Immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
<ul style="list-style-type: none"> Managing/co-managing public offering of securities Investment banking/merchant banking/brokerage services products or services other than those above in connection with research report 	No
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

For More Information Visit Us At : www.spasecurities.com

SPA CAPITAL SERVICES LIMITED

Investment Advisory services,
AMFI Reg. No. ARN-0007

SPA CAPITAL ADVISORS LIMITED

SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825

SPA COMTRADE PRIVATE LIMITED

SPA INSURANCE BROKING SERVICES LTD

Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03

SPA Securities Ltd SEBI Reg. Nos.

NSE Cash	INB231178238
NSE Future & Option	INF231173238
NSE Currency Derivatives	INE231178238
BSE Cash	INB011178234
BSE Currency Derivatives	INE011178234
MCX-SX Cash	INB261178231
MCX-SX Future & Option	INF261178231
MCX-SX Currency Derivatives	INE261178238
Mutual Fund	ARN 77388
CDSL DP	IN-DP-CDSL-485-2008
NSDL DP	IN-DP-NSDL-316-2009
SEBI Research Analyst	INH100002615